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Background: Malaria during pregnancy results in adverse outcomes for mothers and infants. Intermittent
preventive treatment (IPT) with sulphadoxine-pyrimethamine (SP) is the primary intervention aimed at reducing
malaria infection during pregnancy. Although submicroscopic infection is common during pregnancy and at
delivery, its impact throughout pregnancy on the development of placental malaria and adverse pregnancy
outcomes has not been clearly established.
Methods: Quantitative PCR was used to detect submicroscopic infections in pregnant women enrolled in an
observational study in Blantyre, Malawi to determine their effect on maternal, foetal and placental outcomes. The
ability of SP to treat and prevent submicroscopic infections was also assessed.
Results: 2,681 samples from 448 women were analysed and 95 submicroscopic infections were detected in 68
women, a rate of 0.6 episodes per person-year of follow-up. Submicroscopic infections were most often detected
at enrolment. The majority of women with submicroscopic infections did not have a microscopically detectable
infection detected during pregnancy. Submicroscopic infection was associated with placental malaria even after
controlling for microscopically detectable infection and was associated with decreased maternal haemoglobin at
the time of detection. However, submicroscopic infection was not associated with adverse maternal or foetal
outcomes at delivery. One-third of women with evidence of placental malaria did not have documented peripheral
infection during pregnancy. SP was moderately effective in treating submicroscopic infections, but did not prevent
the development of new submicroscopic infections in the month after administration.
Conclusions: Submicroscopic malaria infection is common and occurs early in pregnancy. SP-IPT can clear
some submicroscopic infections but does not prevent new infections after administration. To effectively control
pregnancy-associated malaria, new interventions are required to target women prior to their first antenatal care visit
and to effectively treat and prevent all malaria infections.
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Each year, 25 million pregnant women in sub-Saharan
Africa are at risk for malaria infection. Malaria during
pregnancy is associated with maternal anaemia and in-
fant low birth weight. Malaria during pregnancy is es-
timated to result in 100,000 infant deaths annually in
Africa [1].
Malaria infections during pregnancy may be identified
by microscopic examination of a blood smear or may be
submicroscopic, detectable only by more sensitive mo-
lecular methods. Studies in a variety of transmission set-
tings have shown that submicroscopic infections can be
up to five times more common than microscopic in-
fections during pregnancy [2-7]. While the associations
between microscopically detectable malaria during preg-
nancy and maternal anaemia at delivery and low birth
weight have been supported in most studies [1], the
impact of submicroscopic infection during pregnancy
on these adverse outcomes has not been systematic-
ally assessed.
Because malaria infections during pregnancy are often
asymptomatic, a key intervention to decrease the burden
of malaria in pregnancy is intermittent preventive treat-
ment (IPT), providing anti-malarial chemotherapy at
routine intervals during pregnancy. Currently, the rec-
ommended anti-malarial chemotherapy for IPT in the
majority of Africa is sulphadoxine-pyrimethamine (SP),
which is intended to cure current infections and to pro-
vide a period of post-treatment prophylaxis to prevent
future infections.
In much of sub-Saharan Africa, increasing resistance
to SP [8] is generating concerns that SP-IPT efficacy will
be compromised [9]. Understanding the relative import-
ance of the treatment and prophylactic effects of SP-IPT
and the differential impact of resistance on these effects
may have implications for the selection of a new drug to
replace SP for IPT.
In the context of an observational study of a large co-
hort of pregnant women in Malawi, the effect of sub-
microscopic infections on maternal and foetal outcomes
was examined. All women received SP-IPT according to
the national policy. At each visit a blood smear was ex-
amined and women were treated for malaria infections
detected by microscopy. The primary analysis of infec-
tions detected solely by microscopy showed an associ-
ation between infection at enrolment in antenatal care
and placental malaria, but only infections detected at the
time of delivery were associated with adverse pregnancy
outcomes [10]. Because higher rates of submicroscopic
infection than microscopically detectable infection were
anticipated and submicroscopic infections were not trea-
ted, it was hypothesized that submicroscopic infections
would be associated with placental malaria, maternal
anaemia and infant low birth weight. It was furtherhypothesized that, due to high rates of SP resistance,




Four-hundred and fifty pregnant women were enrolled
in an observational cohort study of malaria during preg-
nancy in Blantyre, Malawi between June 2009 and June
2010. All women were in their first or second pregnancy
and were less than or equal to 28 weeks gestational age
based on clinical assessment at enrolment. Women were
followed monthly during pregnancy and encouraged to
come to the clinic if they had intercurrent illness. At
each encounter, peripheral blood smears and dried blood
spots on filter paper were collected. At delivery, these
same specimens and placental blood and tissue samples
were collected. After quickening, women received SP-IPT
up to three times separated by at least four weeks. Women
with malaria detectable by blood smear at routine or sick
visits were treated for malaria in accordance with the
national guidelines (quinine in the first trimester and
artemether-lumefantrine in the second and third tri-
mesters). Details are described by Kalilani-Phiri et al. [10].
Laboratory procedures
Microscopy
Peripheral blood slides were Field’s stained and exam-
ined using a 100× oil immersion objective to detect and
quantify parasitaemia using an estimated white blood
cell count of 8,000 per microlitre. A diagnosis of micro-
scopically detectable malaria infection was made when
asexual stage malaria parasites were detected on a thick
film. A smear was recorded as negative after examining
100 high power fields. Two microscopists read all slides;
in cases of disagreement between the readings, a third
expert reader adjudicated.
Haemoglobin
Haemoglobin measurement was obtained from a finger
prick blood samples using HemoCue® AB.
Placental biopsies
Placental biopsies were preserved in 10% neutral buff-
ered formalin, embedded in paraffin wax, cut into four
micron thick sections, and then stained with haematoxy-
lin and eosin. Slides were examined for presence of mal-
aria parasites and haemozoin pigment.
Molecular detection
DNA was extracted from frozen placental samples and
dried blood spots of peripheral blood and placental blood.
Quantitative real time polymerase chain reaction (qPCR)
was used to detect the gene for Plasmodium falciparum
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described on our website [11].
Data analysis
Peripheral blood infections were categorized as either
microscopic (smear positive, confirmed by qPCR) or sub-
microscopic (smear negative, but qPCR positive). An epi-
sode of submicroscopic infection was defined as a positive
qPCR and a negative malaria smear obtained at the same
time. Sequential episodes of submicroscopic parasitaemia
were only counted once. Gestational age at enrolment was
calculated based on the last menstrual period or by the
fundal height if the last menstrual period was not known.
Gestational age at birth was determined based on the last
menstrual period and the Ballard score. Fundal height at
enrolment was included in the estimate of gestational age
at birth if the last menstrual period and Ballard estimates
were more than two weeks’ discrepant. The first trimester
was defined as conception through 13 weeks and the sec-
ond trimester was from 14 through 27 weeks. Low birth
weight was defined as birth weight less than 2,500 g. To
further investigate low birth weight, preterm birth and
small for gestational age were analysed separately. If the
gestational age at delivery was less than 37 weeks, the de-
livery was classified as preterm. Infants were considered
small for gestational age if the birth weight for gestational
age, based on WHO growth curves, was less than a Z-
score of −2. Fever was defined as a measured axillary
temperature ≥37.5°C. Maternal anaemia was defined as
haemoglobin <11.0 g/dL. Placental malaria was classified
as the presence of haemozoin pigment or parasites, by ei-
ther histology or qPCR. Submicroscopic placental malaria
was defined as parasites detected by qPCR, but not hist-
ology. Only women with both molecular and histological
placental results were included in descriptive analyses of
placental malaria. However, women missing histological
results were included in analysis of the presence or ab-
sence of placental malaria because detection of parasites
by qPCR alone is sufficient to categorize them as having
placental malaria. Data from twin gestations were in-
cluded in analyses of placental malaria but excluded from
analyses of birth outcomes. Analyses of the effects of SP
were restricted to visits that occurred within 28 days after
the first visit.
Data analysis was performed using STATA version 12.1
software (Stata Corp, College Station, TX, USA). Student’s
t-tests or Wilcoxon rank-sum were used for comparisons
of normal and non-normal distributions of continuous
variables, respectively. Chi-squared and Fisher’s exact tests
were used for comparisons of proportions. Odds ratios
were calculated using univariate and multivariate lo-
gistic regression. Analyses of haemoglobin during preg-
nancy were controlled for gestational age and adjusted
for repeated measurements using robust cluster varianceestimation. All P-values are two-sided, and statistical sig-
nificance was set at P ≤0.05.
Ethical considerations
Ethical approval was obtained from the University of
Malawi College of Medicine Research and Ethics Commit-
tee and the University of Maryland Baltimore Institutional
Review Board. Written informed consent was obtained
from all participants before conducting any study related
activities. Participants had the option to withdraw from
the study at any time. All data were recorded and analysed
anonymously.
Results
Two thousand six hundred and eighty-one peripheral
blood samples from 448 women enrolled in the study were
screened for submicroscopic infection. Two women were
not included in the analysis because they did not have any
filter papers available for molecular analysis. Ninety-five
incident submicroscopic infections were detected in 68
women. Pregnant women had 0.6 episodes of submicro-
scopic malaria per person-year of follow-up. As previously
published, women in this cohort also experienced 0.6 epi-
sodes of microscopically detected infection per person-
year of follow-up [10]. Thus, the overall rate of malaria
infection was 1.2 episodes per person year of follow up.
Among women with submicroscopic infections, the
mean number of infections was 1.4 (95% CI 1.2-1.6, range
1–5). Forty-nine women (72%) with submicroscopic in-
fections never had an infection detected by microscopy
during pregnancy. Submicroscopic infection was not asso-
ciated with first versus second pregnancy, age, bed net use,
or malaria treatment during pregnancy prior to enrol-
ment, but was associated with enrolment at an earlier ges-
tational age, more frequent visits, and lack of secondary
school attendance (Table 1). Gestational age at enrolment
was inversely correlated with number of visits.
Among 311 placentas with both histological and mo-
lecular data available for evaluation, 104 (33%) had evi-
dence of placental malaria (Figure 1). Thirty-three (11%)
had both parasites and haemozoin detected microsco-
pically. Three (1%) had no haemozoin but did have pa-
rasites detected by histology and confirmed by qPCR.
Thirty-eight (12%) had haemozoin without histological
or molecular evidence of active parasite infection. Thirty
(10%) had submicroscopic infection with no histological
evidence of parasites or haemozoin.
Histological results were not available for six placentas;
all had parasites detected by qPCR.
Timing and clinical presentation of submicroscopic
infection
Among women with at least one submicroscopic infection,
69% had submicroscopic infection detected at enrolment
Table 1 Enrolment characteristics of women with and without submicroscopic infection detected during pregnancy
irrespective of the presence of microscopic infection
Submicroscopic
infection (N = 68)
No submicroscopic
infections (N = 380)
p-value
Mean gestational age in weeks (95% CI) 18.9 (17.8-20.1) 20.3 (19.9-20.7) 0.04
Mean age in years (95% CI) 20.1 (19.3-20.8) 20.1 (19.8-20.4) 0.9
Primigravid (%) 37 (54%) 247 (65%) 0.1
Did not attend secondary school (%) 33 (49%) 106 (28%) 0.001
Slept under bed net last night (%) 31 (46%) 194 (51%) 0.3m
Treated for malaria during pregnancy but prior to enrolment (%) 8 (12%) 57 (15%) 0.4
Mean number of visits (95% CI) 6.4 (5.6-7.2) 5.4(5.1-5.7) 0.01
CI: confidence interval.
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trimester and at delivery. Based on estimated gestational
age at enrolment, submicroscopic infection was detected in
12% (6/50) of first trimester, 6% (63/1,050) of second tri-
mester, and 1.4% (19/1,372) of third trimester samples
prior to delivery. These infections occurred in six, fifty-six,
and eighteen women, respectively. Twelve women had in-
fection in more than one trimester. After excluding the
submicroscopic infections present at enrolment, the preva-
lence of submicroscopic infection was higher in the second
trimester than the third trimester [22/650 (3.4%) versus 19/
1,372 (1.4%) of samples, p = 0.003].
Nine of 308 women (3%) with peripheral samples ob-
tained at delivery had submicroscopic infection. Two wo-



























Figure 1 Frequency of histological and molecular findings of placentasubmicroscopic infection at their last antepartum visit,
thus infection at delivery was not considered a new sub-
microscopic infection.
Submicroscopic infection was not associated with doc-
umented fever (p = 0.4) or reported fever within 48 hours
prior to the visit (p = 0.2). Three women reported cough,
sneezing and body pains at a visit during which submi-
croscopic infection was detected. Otherwise, no women
reported any symptoms of illness during visits at which
submicroscopic infection was detected. However, sub-
microscopic infection was associated with a 0.6 g/dL
decrease in mean haemoglobin at the time of detec-
tion (11.5 g/dL vs 12.1 g/dL, p = 0.001). This decrease
remained significant after adjusting for gestational age
and repeated measurements.bmicroscopic 
ental malaria & 
mozoin N=25
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Table 2 Association of submicroscopic infection during







No infection 39/110 (35%) 184/207 (89%) Referent
Submicroscopic
infection
37/110 (34%) 14/207 (7%) 7.5 (3.6-15.6)
Microscopic infection 49/110 (45%) 10/207 (5%) 16.6 (7.7-35.8)
CI: confidence interval.
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Women who had submicroscopic infections were more
likely to have placental malaria than those without in-
fections. After controlling for microscopically detectable
infection, women with submicroscopic infection were
more than seven-fold more likely to have placental mal-
aria than women without any documented infection dur-
ing pregnancy (Table 2). Each additional episode of
submicroscopic infection increased the risk of placental
malaria nearly five-fold (OR 4.9, 95% CI 2.7-9.1, p <
0.001). All women with submicroscopic infection detec-
ted in peripheral blood at delivery had placental malaria.
Thirty-five percent (39/110) of women who had evi-
dence of placental malaria did not have any microscopic
or submicroscopic peripheral infections detected during
pregnancy or at delivery.
Among women without microscopic infection during
pregnancy, submicroscopic infection detected at enrol-
ment was more strongly associated with placental malaria
than submicroscopic infection detected after enrolment.
After excluding infections detected at enrolment, third tri-
mester infections were more strongly associated with pla-
cental malaria than second trimester infections (Table 3).
Submicroscopic infection during pregnancy, at delivery
or in the placenta was not associated with adverse ma-
ternal or foetal outcomes. The overall rates of these ad-
verse outcomes were: 18% low birth weight, 13% small
for gestational age, 15% preterm delivery and 11% mater-
nal anaemia at delivery. The prevalence of these out-
comes was the same in women who did and did not
have submicroscopic infection in their peripheral blood
or placenta (Table 4).Table 3 Timing of submicroscopic infection during pregnancy
microscopically detected infection
Timing of submicroscopic infection detection Any p
No submicroscopic infection 39/61
Submicroscopic infection at enrolment visit* 19/60
Submicroscopic infection at a follow-up visit in the 2nd trimester 6/61 (
Submicroscopic infection at a follow-up visit in the 3rd trimester 7/61 (
*Four women did not have molecular data available from their enrolment visit.
CI: confidence interval.Effect of SP-IPT on submicroscopic infections
The ability of SP to clear submicroscopic infections was
evaluated by examining women who had submicroscopic
infection and a subsequent visit within 28 days (N = 79
visits). Women who received a dose of SP when they had
a submicroscopic infection were less likely to have an in-
fection at their next visit within 28 days than women with
submicroscopic infections who did not receive SP (23.9 vs
48.5%; p = 0.02).
The prophylactic efficacy of SP was assessed by com-
paring the rates of malaria infection within 28 days in
women who did and did not receive SP when they had
no malaria infection. A total of 1,779 visits were in-
cluded in the analysis. Women who did and did not re-
ceive SP had the same rate of parasitaemia within the
next 28 days (2.0 vs 2.2%; p = 0.83) (Figure 2).
Discussion
Even with adherence to SP-IPT administration three times
during pregnancy and active case detection and treatment
of malaria, submicroscopic infection of the peripheral
blood during pregnancy is frequent, especially at the first
antenatal visit. Low-density malaria infections, detected
only by molecular methods, are associated with placental
malaria infection and a decrease in maternal haemoglobin
levels. SP-IPT appears to treat some submicroscopic infec-
tions but does not prevent new infections. These findings
have important implications for the development of fur-
ther interventions for prevention of malaria pregnancy.
This is the first report of the effect of submicroscopic
infection throughout pregnancy on maternal and foetal
outcomes. Prior studies of submicroscopic malaria during
pregnancy have been limited by being cross-sectional, ra-
ther than longitudinal in nature [2,3,6,7,12-15]. Linking
antenatal infections to specific delivery and neonatal
outcomes is essential to evaluating the importance of
submicroscopic infections and designing strategies to
optimize maternal and infant health.
The results are consistent with previous studies indi-
cating that submicroscopic infection is associated with
anaemia at the time of detection [12,15]. Two previous
studies reported an association between submicroscopic
infection at delivery and infant low birth weight [6] orand odds of placental malaria among women without
lacental malaria No placental malaria Odds ratio (95% CI)
(64%) 184/197 (93%) Referent
(32%) 9/194 (5%) 6.9 (2.7-17)
10%) 3/197 (2%) 1.9 (0.3-12)
11%) 2/197 (1%) 3.5 (0.5-23)
Table 4 Maternal and foetal outcomes in singleton, live births from women with only submicroscopic infection compared to women without infection during
pregnancy, at delivery or in the placenta
Only submicroscopic
infection during
pregnancy (N = 35)
No infection during
pregnancy (N = 228)
p-value Submicroscopic
infection at








malaria (N = 198)
p-value
Mean birth weight in kg (95% CI) 2.9 (2.7-3.1) 2.8 (2.78-2.90) 0.7 3.2 (2.9-3.6) 2.8 (2.8-2.9) 0.3 2.8 (2.6-2.9) 2.8 (2.8-2.9) 0.5
Low birth weight (%) 5 (14%) 40 (17%) 0.6 1 (11%) 42 (16%) 1.0 12 (23%) 31 (16%) 0.3
Mean gestational age in weeks (95% CI) 39 (37–40) 39 (38-39) 1.0 40 (39-41) 39 (38-39) 0.3 39 (38-40) 39 (38-39) 0.8
Preterm delivery (%) 2 (6%) 40 (17%) 0.1 0 (0%) 35 (13%) 0.6 6 (12%) 25 (13%) 0.8
Small for gestational age (%) 2 (6%) 29 (13%) 0.4 0 (0%) 28 (10%) 1.0 8 (15%) 20 (10%) 0.3
Mean maternal [Hb] in g/dL at
delivery (95% CI)
12.9 (12.4-13.3) 12.9 (12.7-13.1) 1.0 12.7 (11.0-14.3) 12.9 (12.8-13.1) 0.6 12.9 (12.5-13.3) 12.9 (12.7-13.1) 0.9



















Figure 2 SP-IPT treatment of submicroscopic infection and prevention of any infection.
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these cross-sectional studies took place prior to, or as
part of, IPT trials and did not assess previous exposure
to or treatment of malaria infection during pregnancy.
Thus, submicroscopic infection may have been a marker
of frequent malaria exposure or lack of IPT administra-
tion prior to delivery. Due to detailed follow-up and
treatment of microscopically detectable infection, the
results of this study more accurately reflect the spe-
cific contribution of submicroscopic infections to clinical
outcomes.
The lack of association between submicroscopic infec-
tion during pregnancy and adverse outcomes despite the
strong association with placental malaria may have been
a function of the design of the study and the clinical care
the participants received. The results from the exami-
nation of the effect of microscopically detectable infec-
tions on maternal and foetal outcomes yielded similar
results, as published previously [10]. The combination of
three doses of SP-IPT and active case detection and
treatment may have protected against adverse effects. It
is also possible that other interventions, such as scree-
ning for anaemia or the appropriate treatment of non-
malaria infections, might have improved the overall health
of women, decreasing the frequency of adverse outcomes.
Given the low prevalence of adverse outcomes, sample
size also limited the ability to detect associations. Previous
studies have demonstrated a 50% increase in rates of low
birth weight [6] and maternal anaemia [7] at delivery asso-
ciated with malaria during pregnancy. This study had only
15 and 7% power to detect a 50% increase in low birth
weight and maternal anaemia at delivery, respectively, gi-
ven the baseline rates of these outcomes in this cohort.
The presence of placental malaria infection in women
who did not have any peripheral malaria infection de-
tected during pregnancy was unexpected. This pheno-
menon may be due to transient infections that were not
captured during sampling intervals. Results from thisstudy indicate that pregnant women frequently clear sub-
microscopic infections spontaneously. Another source of
the placental malaria infection may be infection that oc-
curred prior to enrolment in antenatal care. The strong
association between malaria at enrolment and placental
infection suggests that early infection, even those that
had been cleared at the time of the first antenatal visit,
may have the greatest likelihood of causing placental
pathology.
The modest efficacy of SP in clearing submicroscopic
infection and the lack of prophylactic efficacy likely re-
flects the high level of SP resistance among malaria par-
asites in Malawi [8,16]. This is consistent with studies of
SP-IPT in infants, that showed the protective effect of
SP was approximately one month and the duration of
this protective efficacy is inversely related to presence
of in vitro markers of SP resistance [17,18].
There are several important features of this study that
may limit the generalizability of the findings. Women
had an average of six visits during the study and were
screened with microscopy at each encounter. Thus, wo-
men received more screening and treatment when partici-
pating in the study than they would have during routine
antenatal care. Despite the intensive follow-up and me-
dical attention provided in the study, submicroscopic in-
fection is strongly associated with placental malaria and
anaemia during pregnancy. In real life settings, the associ-
ation between submicroscopic malaria and adverse out-
comes would likely have been more pronounced. Having
few encounters during the first trimester and having
samples obtained intermittently limited analysis of the
timing of infection leading to placental infection. Women
with submicroscopic infection did have more visits during
the study, suggesting that increasing sampling frequency
would increase detection of submicroscopic infection. Al-
ternatively, women with submicroscopic infections may
have symptoms leading them to present to the ante-
natal clinic more frequently. However, there was not an
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routine versus sick visit.
These results have important implications for the de-
velopment of alternatives to SP-IPT for prevention of
malaria pregnancy. Two possible strategies are inter-
mittent screening and treatment or IPT with an anti-
malarial more effective than SP. In one trial, intermittent
screening and treatment has been shown to be equi-
valent to SP-IPT [19]. The intermittent screening and
treatment arm in that study used antigen-detecting rapid
diagnostic tests for screening. The parasite density thresh-
old for detection for rapid diagnostic tests, like that for
microscopy, is ten- to 100-fold higher than for qPCR
[20,21]. Rapid diagnostic tests, like microscopy, will fail
to detect infection at the submicroscopic level. Thus, a
rapid diagnostic test-based screening and treatment stra-
tegy will fail to detect infections that this study demon-
strates are associated with placental malaria. Within the
context of the usual antenatal package of four antenatal
visits in pregnancy if IPT is not provided, many micro-
scopic and all submicroscopic infections will not be
treated. Under these conditions, with prolonged and
untreated episodes of low-density malaria infection, it
is expected that the adverse effects of placental mal-
aria would occur [22-24].
If IPT with a more effective anti-malarial is con-
sidered, for example as in ongoing trials of IPT with
dihydroartemisinin-piperaquine [25], azithromycin com-
bined with chloroquine [26] and mefloquine [27], it will
be important to characterize the treatment and prophylac-
tic effect of candidate drugs. Most drug efficacy trials
examine the ability of a drug to cure the infection at the
time of drug administration. However, IPT is most benefi-
cial in high transmission settings if it cures current infec-
tions and prevents subsequent infections. The results of
this study indicate that the loss of prophylactic efficacy
may precede the loss of curative efficacy. Thus, in trials of
alternative anti-malarials for IPT, prophylactic efficacy
should be included as an outcome measure.
The finding that the highest rates of asymptomatic
and submicroscopic malaria are detected in women at
their first antenatal care visit highlights an essential short-
coming of the current policies to prevent pregnancy-
associated malaria. Interventions such as the distribu-
tion of bed nets at antenatal clinics and the adminis-
tration of IPT are delayed until women seek antenatal
care. In Malawi, as in other countries in sub-Saharan
Africa, this is typically late in the second or into the
third trimester [28]. By the time women have their first
antenatal visit, peripheral and placental infection has al-
ready been established. Innovative interventions that can
target women early in pregnancy, or even prior to preg-
nancy, are urgently needed to further decrease the burden
of malaria during pregnancy.Conclusions
Submicroscopic malaria infection is common, occurs early
in pregnancy and is associated with placental malaria.
SP-IPT appears to treat some submicroscopic infections
but does not prevent new infections. To effectively con-
trol pregnancy-associated malaria, new interventions are
required to target women prior to their first antenatal
care visit and to effectively treat and prevent all malaria
infections.
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